BioSupply Trends Quarterly logo
Close this search box.
Winter 2022 - Critical Care

Transition from Clinic- to Home-Based IVIG/SCIG Is Successful to Decrease Exposure to COVID-19

A recent study shows transition of clinic-based to home-based intravenous immune globulin (IVIG)/subcutaneous IG (SCIG) infusion can be successfully done to decrease potential exposure during a pandemic in a high-risk immunosuppressed population, with no impact on patient satisfaction, adherence or efficacy. In addition, home-based infusions were associated with a reduction in costs to patients and an increase in available chair time in the infusion clinic.

In the study, criteria were developed to identify high-risk immunosuppressed patients who would be appropriate candidates for potential conversion to home-based IVIG infusions. Data were collected via chart review, and cost analysis was performed using Medicare Part B reimbursement data. A patient outcome questionnaire was developed for administration through follow-up phone calls.

From March 2020 to May 2020, 45 patients met criteria for home-based infusion, with 27 patients (60 percent) agreeing to it. Posttransition patient outcomes assessment, conducted in 26 patients (96 percent), demonstrated good patient understanding of the home-based infusion process. No infusion-related complications were reported, and 24 patients (92 percent) had no concerns about receiving future IVIG and/or SCIG doses at home. No patient tested positive for COVID-19 during the study period. Clinic infusion visits decreased by 26.6 visits per month, resulting in a total of 106 hours of additional available infusion chair time per month and associated cost savings of $12,877.


Perreault S, Schiffer M, Clinchy-Jarmoszko V, et al. Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion. Am J Health Syst Pharm 2021 Jun 7;78(12):1112- 1117.

BSTQ Staff
BioSupply Trends Quarterly [BSTQ] is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace. With timely and critical information, each themed issue covers topics ranging from product breakthroughs, industry insights and innovations, up-to-the-minute news on the latest clinical trials, accessibility, and service and safety concerns.